A Study of CS-3150 to Evaluate Efficacy and Safety in Hypertensive Patients with Type 2 Diabetes and Albuminuria

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223238

Enrollment

Registered

2016-06-09

Start date

2016-07-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension with type 2 diabetes and albuminuria.

Interventions

investigational material(s) Generic name etc : CS-3150 INN of investigational material : Esaxerenone Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational mat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Male and female subjects aged 20 to 80 years at informed consent 2) Subjects with type 2 diabetes and albuminuria (urine albumin-to-creatinine ratio >= 30, = 140 mmHg, = 80 mmHg, = 30 mL/min/1.73m^2

Exclusion criteria

Exclusion criteria: 1)Secondary hypertension or malignant hypertension 2)Type 1 diabetes 3)Secondary glucose intolerance 4)Diagnosed with non-diabetic nephropathy 5)Serum potassium level = 4.8 mEq/L

Design outcomes

Primary

Measure	Time frame
safety efficacy - Change from baseline in sitting systolic and diastolic blood pressure at the end of treatment - Adverse events	—

Secondary

Measure	Time frame
safety -Time course of sitting systolic and diastolic blood pressure -Proportion of patients achieving sitting blood pressure control -Change rate from baseline in urine-albumin-to-creatinine ratio. -Time course of urine-albumin-to-creatinine.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026